A clinical first-line drug for prevention and treatment of neutropenia after tumor chemoradiotherapy
Since its introduction into the market in 2001, WHITE-C has been clinically applied for more than 20 years, with a wide range of evidence-based applications, topping the list of domestic similar products in terms of export volume. As strict in-house control quality standards are followed, WHITE-C is not only in line with Chinese Pharmacopoeia, but also European Pharmacopoeia. Registered into and sold in 22 countries and regions.
● Neutropenia due to cancer chemotherapy and other reasons
● Neutropenia due to chemotherapy for acute leukemia